Additionally, our data showed that in both PS19 murine model and postmortem tissues from AD and AD/LATE patients, phosphorylated tau burden correlated positively with TMEM106B immunoreactivity, possibly suggesting a conserved role that TMEM106B plays in tauopathy. The gene discussed is MAPT; the disease is Alzheimer disease.